Trial
NCT05288023
Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of California, San Francisco
Collaborators
Bill and Melinda Gates Foundation; Ministry of Health, Niger
Condition
Resistance Bacterial
Intervention
Azithromycin for Oral Suspension
Why stopped
AVENIR I demonstrated efficacy of azithromycin MDA targeted to children 1-59 over 1-11 months in July 2023, thus this trial was stopped before outcomes were collected so Niger could expand the program nationally to include children 1-59 months.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-28